RSS   Newsletter   Contact   Advertise with us
Post Online Media

Matthew Sherman joins Pulmatrix board

Matthew L ShermanPulmatrix, a pharmaceutical company, announced that it has appointed Matthew L. Sherman as a new member to its board of directors.
Article continues below

READ MORE Pulmatrix appoints Mark Iwicki as chairman

Dr. Sherman, Executive Vice President and Chief Medical Officer of Acceleron Pharma, Inc., a clinical stage biopharmaceutical company, has extensive experience in drug development.

Before joining Acceleron in 2006, he was head of clinical research and regulatory affairs at Synta Pharmaceuticals (now Madrigal Pharmaceuticals, Inc.), and leader of clinical development in both oncology and hematology at Wyeth.

Previously, he also held leadership positions at Genetics Institute.

Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the Dana-Farber Cancer Institute and Brigham and Women's Hospital.

 LATEST MOVES FROM Massachusetts 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy